Literature DB >> 9698918

Pulmonary biology of anti-interleukin 5 antibodies.

R W Egan1, D Athwahl, C C Chou, R W Chapman, S Emtage, C H Jenh, T T Kung, P J Mauser, N J Murgolo, M W Bodmer.   

Abstract

Interleukin-5 (IL-5) is a critical cytokine for the maturation of eosinophil precursors to eosinophils in the bone marrow and those eosinophils then accumulated in the lungs during asthma. We have studied anti IL-5 antibodies on allergic responses in mice, guinea pigs and monkeys and are extending this experiment into humans with a humanized antibody. In a monkey model of pulmonary inflammation and airway hyperreactivity, we found that the TRFK-5 antibody blocked both responses for three months following a single does of 0.3 mg/kg, i.v. This antibody also blocked lung eosinophilia in mice by inhibiting release from the bone marrow. To facilitate multiple dosing and to reduce immunogenicity in humans, we prepared Sch 55700, a humanized antibody against IL-5. Sch 55700 was also active against lung eosinophilia in allergic monkeys and mice and against pulmonary eosinophilia and airway hyperresponsiveness in guinea pigs. Furthermore, as opposed to steroids, Sch 55700 did not cause immunosuppression in guinea pigs. Studies with this antibody in humans will be critical to establishing the therapeutic potential of IL-5 inhibition.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9698918     DOI: 10.1590/s0074-02761997000800011

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  8 in total

Review 1.  Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.

Authors:  Zhaleh J Amini-Vaughan; Margarita Martinez-Moczygemba; David P Huston
Journal:  Curr Allergy Asthma Rep       Date:  2012-10       Impact factor: 4.806

Review 2.  Reslizumab in Eosinophilic Asthma: A Review.

Authors:  Emma D Deeks; Guy Brusselle
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

3.  Allergen-induced murine upper airway inflammation: local and systemic changes in murine experimental allergic rhinitis.

Authors:  H Saito; K Howie; J Wattie; A Denburg; R Ellis; M D Inman; J A Denburg
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

Review 4.  The consequences of not having eosinophils.

Authors:  G J Gleich; A D Klion; J J Lee; P F Weller
Journal:  Allergy       Date:  2013-06-06       Impact factor: 13.146

5.  Allergy, asthma, and inflammation: which inflammatory cell type is more important?

Authors:  Redwan Moqbel; Solomon O Odemuyiwa
Journal:  Allergy Asthma Clin Immunol       Date:  2008-12-15       Impact factor: 3.406

Review 6.  Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects.

Authors:  Jorge Máspero
Journal:  Ther Adv Respir Dis       Date:  2017-07-06       Impact factor: 4.031

Review 7.  A Review of Respiratory Biologic Agents in Severe Asthma.

Authors:  Nathaniel Johnson; Blessy Varughese; Marianne A De La Torre; Salim R Surani; George Udeani
Journal:  Cureus       Date:  2019-09-18

Review 8.  Reslizumab in the management of poorly controlled asthma: the data so far.

Authors:  Diego Jose Maselli; Maria Ines Velez; Linda Rogers
Journal:  J Asthma Allergy       Date:  2016-08-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.